Form 4: KalVista Pharmaceuticals Executive Paul K. Audhya Reports Stock Transactions
SEC Form 4 Filing
Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including transactions to cover tax obligations.
Summary
- On August 17, 2024, Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, acquired 18,528 shares of common stock through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
- Also on August 17, 2024, Audhya disposed of 2,418 RSUs, 4,027 RSUs and 12,083 PSUs.
- On August 19, 2024, Audhya sold 7,973 shares of common stock at a weighted average price of $12.0133 per share, with prices ranging from $11.47 to $12.35.
- These sales were to cover tax withholding obligations related to the vesting of RSUs and PSUs and were not discretionary transactions.
- Following these transactions, Audhya directly owns 80,880 shares of KalVista Pharmaceuticals common stock, 16,932 RSUs, 20,140 RSUs and 12,084 PSUs.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, as it's a factual report of events.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. It provides transparency to investors regarding insider activity.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, including pharmaceutical companies like KalVista.
- Executive stock transactions are regularly monitored by investors to gauge sentiment and potential future performance.
- Similar filings are made by executives at companies like BioCryst Pharmaceuticals and Ionis Pharmaceuticals.
Stakeholder Impact
- Shareholders are informed about the stock transactions of a key executive.
- The transactions may have a minor impact on the stock price due to the volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| August 17, 2022 | Vesting Commencement Date for 1/16th of total shares subject to RSU, vesting quarterly. |
| November 17, 2022 | Vesting Commencement Date for 1/12th of total shares subject to RSU, vesting quarterly. |
| January 10, 2024 | Date of grant of Performance Stock Units (PSUs) to the Reporting Person. |
| February 17, 2024 | Vesting Commencement Date for 1/4th of total shares subject to PSU, vesting quarterly upon achievement of Performance Metrics. |
| August 17, 2024 | Date of acquisition of 18,528 shares of common stock through vesting of RSUs and PSUs. |
| August 19, 2024 | Date of sale of 7,973 shares of common stock at an average price of $12.0133. |
| August 21, 2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.